Results 151 to 160 of about 9,130,139 (414)
NMDA receptor gene variations as modifiers in Huntington disease: a replication study. [PDF]
, 2011 Several candidate modifier genes which, in addition to the pathogenic CAG repeat expansion, influence the age at onset (AO) in Huntington disease (HD) have already been described.Arning, L, Craufurd, D, de Yebenes, JG, Dose, M, Epplen, JT, Landwehrmeyer, GB, REGISTRY Investigators of the European Huntington's Disease Netw, The, Roos, RA, Saft, C, Tabrizi, SJ, Wieczorek, S +10 morecore Interregional compensatory mechanisms of motor functioning in progressing preclinical neurodegeneration. [PDF]
, 2013 Understanding brain reserve in preclinical stages of neurodegenerative disorders allows determination of which brain regions contribute to normal functioning despite accelerated neuronal loss.Ahmed Abdulkadir, Ashburner, Bartenstein, Bartrés-Faz, Beglinger, Boudrias, Buhmann, Busan, Daunizeau, David, Deichmann, Eickhoff, Elisa Scheller, Feigin, Fox, Friston, Friston, Friston, Friston, Gavazzi, Geyer, Goebel, Granger, Grefkes, Grefkes, Grefkes, Groppa, Holtzer, Iacoboni, Jessica Peter, Kasess, Katzman, Kiebel, Klöppel, Klöppel, Koch, Koch, Kötter, Langbehn, Langbehn, Lee, Lehéricy, Luppino, Marder, Mars, Matelli, McIntyre, Murray, Mühlau, Nachev, Nakamura, Narayana, Nithianantharajah, Nithianantharajah, Nopoulos, Novak, O'Shea, O'Shea, Richard S.J. Frackowiak, Rizzolatti, Rosas, Rounis, Rowe, Rushworth, Rushworth, Sarah J. Tabrizi, Sarfeld, Satz, Scahill, Schluter, Seghier, Stefan Klöppel, Steffener, Stephan, Stephan, Stephan, Stephan, Stern, Stern, Tabrizi, Tabrizi, Tabrizi, Tanaka, The Huntington's Disease Collaborative Research Group, Valenzuela, Walker, Wang, Witt, Wolf, Wolf, Wolf, Wolf, Wolf, Wood, Zeki +94 morecore +1 more sourceUncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data
Clinical Pharmacology &Therapeutics, EarlyView.Although attractive for relevance to real‐world scenarios, real‐world data (RWD) is typically used for drug repurposing and not therapeutic target discovery. Repurposing studies have identified few effective options in neurological diseases such as the rare disease, amyotrophic lateral sclerosis (ALS), which has no disease‐modifying treatments ...Mohammadali Alidoost, Jeremy Y. Huang, Georgia Dermentzaki, Anna S. Blazier, Giorgio Gaglia, Timothy R. Hammond, Francesca Frau, Mary Clare McCorry, Dimitry Ofengeim, Jennifer L. Wilson +9 morewiley +1 more sourceObserving Huntington's disease: the European Huntington's Disease Network's REGISTRY
Journal of Neurology, Neurosurgery & Psychiatry, 2010 BACKGROUND: Huntington's disease (HD) is a rare triplet repeat (CAG) disorder. Advanced, multi-centre, multi-national research frameworks are needed to study simultaneously multiple complementary aspects of HD. This includes the natural history of HD, its management and the collection of clinical information and biosamples for research. METHODS: Orth M, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB, Bachoud Lévi AC, Bentivoglio AR, Biunno I, Bonelli R, Burgunder JM, Dunnett SB, Ferreira JJ, Giuliano J, Handley OJ, Heiberg A, Illmann T, van Kammen D, Landwehrmeye GB, Levey J, Nielsen JE, Päivärinta M, Roos RA, Sebastián AR, Tabrizi SJ, Vandenberghe W, Verellen Dumoulin C, Zaremba J, Uhrova T, Wahlström J, Schwenke C, Orth M, Illmann T, Wallner M, Barth K, Guedes LC, Finisterra AM, Garde MB, Bos R, Burg S, Ecker D, Handley OJ, Held C, Koppers K, Laurà M, Descals AM, McLean T, Mestre T, Minster S, Monza D, Townhill J, Orth M, Padieu H, Paterski L, Peppa N, Koivisto SP, Rialland A, Røren N, Sasinková P, Cubillo PT, Tritsch C, van Walsem MR, Witjes Ané MN, Yudina E, Zielonka D, Zielonka E, Zinzi P, Bonelli RM, Herranhof B, Holl A, Kapfhammer HP, Koppitz M, Magnet M, Otti D, Painold A, Reisinger K, Scheibl M, Hecht K, Lilek S, Müller N, Schöggl H, Ullah J, Brugger F, Hepperger C, Hotter A, Mahlknecht P, Nocker M, Seppi K, Wenning G, Buratti L, Hametner EM, Holas C, Hussl A, Mair K, Poewe W, Wolf E, Zangerl A, Braunwarth EM, Lilek S, Sinadinosa D, Walleczek AM, Bonelli RM, Ladurner G, Staffen W, Ribaï P, Verellen Dumoulin C, Flamez A, Morez V, de Raedt S, Boogaerts A, Vandenberghe W, van Reijen D, Klempíř J, Kucharík M, Roth J, Šenkárová Z, Hasholt L, Hjermind LE, Jakobsen O, Nørremølle A, Sørensen SA, Stokholm J, Nielsen J, Hiivola H, Martikainen K, Tuuha K, Peippo M, Sipponen M, Ignatius J, Kärppä M, Åman J, Santala M, Allain P, Guérid MA, Gohier B, Olivier A, Prundean A, Scherer Gagou C, Verny C, Babiloni B, Debruxelles S, Goizet C, Lafoucrière D, De Bruycker C, Carette AS, Decorte E, Delval A, Delliaux M, Dujardin K, Peter M, Plomhouse L, Simonin C, Thibault Tanchou S, Bellonet M, Duru C, Krystkowiak P, Roussel M, Wannepain S, Azulay JP, Chabot C, Delphini M, Eusebio A, Grosjean H, Mundler L, Nowak M, Rudolf G, Steinmetz G, Tranchant C, Wagner C, Zimmermann MA, Calvas F, Cheriet S, Démonet JF, Galitzky M, Kosinski CM, Milkereit E, Probst D, Sass C, Schiefer J, Schlangen C, Werner CJ, Gelderblom H, Priller J, Prüss H, Spruth EJ, Andrich J, Hoffmann R, Kraus PH, Muth S, Prehn C, Saft C, Salmen S, Stamm C, Steiner T, Strassburger K, Lange H, Friedrich A, Hunger U, Löhle M, Ganos C, Schrader C, Reilmann R, Landwehrmeyer B, Capellari S, Rizzo G, Abbruzzese G, Di Maria E, Mandich P, Di Bella D, Gellera C, Mariotti C, Rinaldi C, Russo CV, Cannella M, ROMANO, SILVIA, Frich J, Slawek J, Janik P, Rakowicz M, Cavaco S, Gago M, Barrero F, Calopa M, Gorospe A, Mir P, Paucar M, Svenningsson P, Tedroff J, Miedzybrodzka Z, Busse M, Rosser A, Lahiri N, Tabrizi S, Wild E +234 moreopenaire +10 more sourcesOptimizing Patient Registries for Regulatory Decision Making ‐ Key Learnings From an HMA/EMA Multistakeholder Workshop
Clinical Pharmacology &Therapeutics, EarlyView.The Joint Heads of Medicines Agencies and European Medicines Agency's (HMA/EMA) big data initiative paves the way for better integration of real‐world data, including data from patient registries, into regulatory decisions on medicines. This article focuses on the outcome of a two‐day multistakeholder workshop organized by EMA in 2024, which explored ...Kelly Plueschke, Carla Jonker, Hanna Kankanen, Thorsten Vetter, Bruno Sepodes, Lutz Naehrlich, Jan Hillert, Gracy Crane, Sabine Straus, Paolo Foggi, Simona Martin, Christina Kyriakopoulou, Peter Mol, Francesca Day, Kieran Breen, Neil Bennett, Mencia de Lemus Belmonte, Simon Bennett, Patrice Verpillat, Kit C. B. Roes, Ana Cochino, Franz Schaefer, Jesús María Hernández‐Rivas, Patricia McGettigan, Peter Arlett +24 morewiley +1 more sourceRole for inflammatory markers in predicting right ventricular failure in mechanical assist device recipients
ESC Heart Failure, EarlyView.Abstract
Right ventricular failure (RVF) is a common complication following left ventricular assist device (LVAD) implantation and increases patient morbidity and mortality. Due to the complex and limited understanding of RVF pathophysiology, efforts to prognosticate RVF after LVAD have been challenging.Abdul‐Fatawu Osman, Shane S. Scott, Ebubechukwu O. Ezeh, Evans Osuji, Israel O. Ailemen, Mohamed H. Derbala, Salil Kumar, Asvin M. Ganapathi, Daniel B. Sims, Ashrith Guha, Bryan A. Whitson, Sakima A. Smith +11 morewiley +1 more source
